Aldo-keto reductases and bioactivation/detoxication

被引:299
作者
Jin, Yi [1 ]
Penning, Trevor M. [1 ]
机构
[1] Univ Penn, Sch Med, Ctr Excellence Environm Technol, Dept Pharmacol, Philadelphia, PA 19104 USA
关键词
hormone replacement therapeutics; cancer chemotherapeutics; CNS-acting drugs; polycyclic aromatic hydrocarbons; reactive aldehydes; gene regulation;
D O I
10.1146/annurev.pharmtox.47.120505.105337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aldo-keto reductases (AKRs) are soluble NAD(P)(14) oxidoreductases that primarily reduce aldehydes and ketones to primary and secondary alcohols, respectively. The ten known human AKR enzymes can turnover a vast range of substrates, including drugs, carcinogens, and reactive aldehydes. They play central roles in the metabolism of these agents,and this can lead to either their bioactivation or detoxication. AKRs are Phase I drug metabolizing enzymes for a variety of carbonyl-containing drugs and are implicated in cancer chemotherapeutic drug resistance. They are involved in tobacco-carcinogenesis because they activate polycyclic aromatic trans-dihydrodiols to yield reactive and redox active o-quinones, but they also catalyze the detoxication of nicotine derived nitrosamino ketones. They also detoxify reactive aldehydes formed from exogenous toxicants, e.g., aflatoxin, endogenous toxicants, and those formed from the breakdown of lipid peroxides. AKRs are stress-regulated genes and play a central role in the cellular response to osmotic, electrophilic, and oxidative stress.
引用
收藏
页码:263 / 292
页数:30
相关论文
共 122 条
  • [1] REDOX REGULATION OF FOS AND JUN DNA-BINDING ACTIVITY INVITRO
    ABATE, C
    PATEL, L
    RAUSCHER, FJ
    CURRAN, T
    [J]. SCIENCE, 1990, 249 (4973) : 1157 - 1161
  • [2] FOS AND JUN COOPERATE IN TRANSCRIPTIONAL REGULATION VIA HETEROLOGOUS ACTIVATION DOMAINS
    ABATE, C
    LUK, D
    GAGNE, E
    ROEDER, RG
    CURRAN, T
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (10) : 5532 - 5535
  • [3] THE ROLE OF JUN, FOS AND THE AP-1 COMPLEX IN CELL-PROLIFERATION AND TRANSFORMATION
    ANGEL, P
    KARIN, M
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1072 (2-3) : 129 - 157
  • [4] [Anonymous], 2002, IARC MON EV CARC RIS
  • [5] THE KINETIC MECHANISM CATALYZED BY HOMOGENEOUS RAT-LIVER 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE - EVIDENCE FOR BINARY AND TERNARY DEAD-END COMPLEXES CONTAINING NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    ASKONAS, LJ
    RICIGLIANO, JW
    PENNING, TM
    [J]. BIOCHEMICAL JOURNAL, 1991, 278 : 835 - 841
  • [6] Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction
    Ax, W
    Soldan, M
    Koch, L
    Maser, E
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 59 (03) : 293 - 300
  • [7] Identification and characterization of novel stable deoxyguanosine and deoxyadenosine adducts of benzo[α]pyrene-7,8-quinone from reactions at physiological pH
    Balu, N
    Padgett, WT
    Lambert, GR
    Swank, AE
    Richard, AM
    Nesnow, S
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (06) : 827 - 838
  • [8] Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: Potential antineoplastic agents that work independently of cyclooxygenase isozymes
    Bauman, DR
    Rudnick, SI
    Szewczuk, LM
    Jin, Y
    Gopishetty, S
    Penning, TM
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (01) : 60 - 68
  • [9] Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats
    Behnia, K
    Boroujerdi, M
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1999, 51 (11) : 1275 - 1282
  • [10] BOHREN KM, 1989, J BIOL CHEM, V264, P9547